Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Olanzapine versus haloperidol treatment in first-episode psychosis
Autore:
Sanger, TM; Lieberman, JA; Tohen, M; Grundy, S; Beasley, C; Tollefson, GD;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA Univ N Carolina Chapel Hill NC USA d, Dept Psychiat, Chapel Hill, NC USA Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 Med, Dept Psychiat, Boston, MA 02115 USA Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 th, Dept Epidemiol, Boston, MA 02115 USA
Titolo Testata:
AMERICAN JOURNAL OF PSYCHIATRY
fascicolo: 1, volume: 156, anno: 1999,
pagine: 79 - 87
SICI:
0002-953X(199901)156:1<79:OVHTIF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; SCHIZOPHRENIC-PATIENTS; ANTIPSYCHOTIC-DRUGS; EXTRAPYRAMIDAL SYMPTOMS; CLINICAL-TRIAL; WEIGHT-GAIN; LONG-TERM; FOLLOW-UP; CLOZAPINE; SCALE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Sanger, TM Elis,illy & Co, Lilly Corp Ctr, Lilly Res Labs, Drop Code 0537,Indianapoli Eli Lilly & Co Drop Code 0537 Indianapolis IN USA 46285 anapoli
Citazione:
T.M. Sanger et al., "Olanzapine versus haloperidol treatment in first-episode psychosis", AM J PSYCHI, 156(1), 1999, pp. 79-87

Abstract

Objective: It has been hypothesized that the morbidity and mortality associated with schizophrenia can be prevented by providing effective treatment during the first episode of psychosis. Hence, the authors examined patientswith first-episode psychosis to determine the efficacy and safety of olanzapine and haloperidol treatment. Method: A subpopulation of first-episode patients (N=83) from a large prospective, multicenter, international, double-blind, B-week acute treatment study was evaluated. These patients were selected from a pool of 1,996 patients who had a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder and who also met the following criteria: 1) the length of their current psychotic episode had to be 5 or fewer years, and 2) patients had to be 45 years of age or younger at onset of first psychotic symptoms. Results: Compared to haloperidol, olanzapine showed a statistically significantly greater reduction inthe Brief Psychiatric Rating Scale (BPRS) total and negative scores and inthe Positive and Negative Syndrome Scale total and positive scores. Clinical response (defined as 40% or greater improvement in BPRS total score frombaseline) was also statistically significantly higher in olanzapine-treated patients (67.2%) than in haloperidol-treated patients (29.2%). Olanzapine-treated patients further showed statistically significant improvements in the Simpson-Angus scale and Barnes Akathisia Scale scores, while haloperidol-treated patients showed a worsening on both measures. Compared to olanzapine-treated multiple-episode patients in the parent study, olanzapine-treated first-episode patients achieved an even statistically significantly higher response. Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients. Conclusions: In patients experiencing first-episode psychosis, olanzapine had a risk-benefit profile significantly superiorto that of haloperidol. The study results suggest that novel antipsychoticagents such as olanzapine should be considered as a preferred option in first-episode psychosis, on the basis of both safety and efficacy advantages.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 04:25:14